Cancer rash drug trial halted after just 4 patients
NCT ID NCT04697069
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 21 times
Summary
This study tested a drug called imsidolimab (ANB019) to treat acne-like skin rashes that can happen as a side effect of certain cancer treatments. The trial planned to include people with cancer who were getting EGFR or MEK inhibitor therapy and had at least 20 facial bumps. However, the study was stopped early and only enrolled 4 participants, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNEIFORM ERUPTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 101
St Louis, Missouri, 63110, United States
-
Site 102
Tampa, Florida, 33620, United States
-
Site 103
Houston, Texas, 77030, United States
-
Site 105
Columbus, Ohio, 43215, United States
-
Site 106
Boston, Massachusetts, 02215, United States
-
Site 201
Szczecin, 70-784, Poland
-
Site 203
Poznan, 60-569, Poland
-
Site 204
Gliwice, 44-102, Poland
-
Site 301
Olomouc, 779 00, Czechia
-
Site 302
New Town, Praha 2, 128 00, Czechia
-
Site 303
Brno, 656-91, Czechia
-
Site 304
Plzen-Bory, 305 99, Czechia
-
Site 401
Tbilisi, 0186, Georgia
-
Site 402
Tbilisi, 0144, Georgia
-
Site 403
Tbilisi, 0160, Georgia
-
Site 404
Batumi, 6000, Georgia
-
Site 405
Tbilisi, 0160, Georgia
-
Site 601
Riga, 1038, Latvia
Conditions
Explore the condition pages connected to this study.